Multiple Dose Pharmacokinetics of Intranasal Ketamine

NCT00519987 ↗

Phase 1 Completed 18 enrolled Javelin Pharmaceuticals

NaSingle-groupOpen-label

Summary

This is an open label, single-center study of the pharmacokinetic and safety profile of repeat doses of PMI-150 (intranasal ketamine) 30 mg in healthy adult volunteers.

Timeline

Start: 2007-06
Primary completion: 2007-08
Completion: 2007-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ketamine	Small molecule	30 mg	Intranasal

Indications

No indication recorded.